Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

The CDC reported the mistake involving two vaccines used to treat RSV, a serious respiratory ... Neither of the vaccines, ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees ... heavy-hitting competition. GSK’s Arexvy has been leading the charge in the RSV vaccine sales race so far.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now ... of Abrysvo (manufactured by Pfizer) and Arexvy (manufactured by GlaxoSmithKline), according to the ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

“Should we have an RSV vaccine for older Australians? Absolutely. We have two highly effective vaccines, one made by GSK, one made by Pfizer, which are being implemented and used widely now in ...

Dormitzer also took the lead on Pfizer's respiratory syncytial virus (RSV) vaccine candidates ... now started testing, while GSK has also focused on providing its adjuvant technology to other ...

It's notable, however, that Arexvy's main rival in the RSV vaccine space – Pfizer's Abrysvo – held up much better in the third quarter, with sales slipping only around 5% to $356 million. GSK ...